Background--Myocardial infarction remains the leading cause of morbidity and mortality associated with coronary artery disease. The L-type calcium channel (I Ca-L ) is critical to excitation and contraction. Activation of the channel also alters mitochondrial function. Here, we investigated whether application of a alpha-interacting domain/transactivator of transcription (AID-TAT) peptide, which immobilizes the auxiliary b 2 subunit of the channel and decreases metabolic demand, could alter mitochondrial function and myocardial injury.
M
inimizing myocardial damage and oxidative stress (OS) during reperfusion after ischemia is associated with a decrease in morbidity and mortality. 1 Reperfusion of the ischemic heart during coronary occlusion remains the primary objective to prevent further cardiac damage in the clinical setting. However, the reperfusion period imposes deleterious effects as a result of the generation of reactive oxygen species (ROS) and increases in intracellular calcium ([Ca 2+ ] i , Fura-2) that contribute to development of cardiac hypertrophy and cardiac failure. 2, 3 ROS produced as a result of rapid changes in oxygen can influence the activity of ion channels. The function of the L-type calcium channel (I Ca-L ) is altered during changes in OS as a result of redox modification of the channel protein by H 2 O 2. [4] [5] [6] [7] [8] [9] [10] This leads to an increase in protein synthesis and cell size consistent with the development of myocyte hypertrophy. 11, 12 Increased calcium influx through the channel is sufficient to induce cardiac hypertrophy in mice overexpressing the alpha subunit, 13 and increased expression of the b 2 auxiliary subunit alters contractility and leads to single-channel activity characteristic of heart failure. 14, 15 Therefore, I Ca-L represents a viable target for reduction of injury and prevention of remodeling after ischemia-reperfusion (I/R). I Ca-L is a heterotetramer comprised of the a 1 , b 2 , and a 2 -d subunits. The a 1 subunit contains the pore-forming (S5-S6) and voltage-sensing (S4) regions responsible for ion conductance. The b 2 subunit binds to the a 1 subunit at the alphainteracting domain (AID) and assists with the trafficking and insertion of the a 1 subunit in the cell membrane. 16 The b 2 subunit also regulates inactivation of the current and couples to cytoskeletal proteins. [16] [17] [18] I Ca-L is critical to cardiac excitation and contraction. Activation of the channel can also alter mitochondrial function. Calcium influx through the channel is sufficient to increase cytosolic calcium, mitochondrial calcium uptake, reduction of nicotinamide adenine dinucleotide (NAD + ) to reduced nicotinamide adenine dinucleotide (NADH), superoxide production, and metabolic activity in a calcium-dependent manner. 19 Activation of the channel can also increase mitochondrial membrane potential (MMP). The response is reversible upon inactivation of the channel during voltage clamp and is mediated through the movement of cytoskeletal proteins. 19 Application of a peptide derived against the AID of the channel using a transactivator of transcription (TAT) sequence to facilitate transfer across the membrane (AID-TAT peptide) attenuates the increase in MMP and metabolic activity after activation of the channel. 19 The peptide immobilizes the auxiliary b 2 subunit and induces functional uncoupling from the actin cytoskeleton. 20 Therefore, the channel can modulate mitochondrial function and metabolic activity in cardiac myocytes.
In this study, we tested the efficacy of AID-TAT peptide in reducing damage in hearts exposed to I/R injury ex vivo. We demonstrate that the peptide significantly decreased infarct size. In addition, contractility was improved within 30 minutes after exposure to the peptide ex vivo and up to 12 weeks post-CAL (coronary artery ligation) in rats in vivo. Superoxide production, NADH, flavoprotein oxidation, and metabolic activity were decreased after application of the peptide, suggesting that the peptide "supported" myocardial metabolism during the critical reperfusion period. Therefore, application of the AID-TAT peptide may represent a viable therapy in the prevention of myocardial damage and support of contractile function post-MI (myocardial infarction).
Methods

Synthesis of Peptides
A peptide corresponding to the a 1 -b interaction domain in the I-II linker of the a 1C subunit was synthesized using the amino acid sequence, QQLEEDLKGYLDWITQAE 20 (Auspep Pty. Ltd., Parkville, VIC, Australia). The scrambled peptide control was also synthesized (QKILGEWDLAQYTDQELE). A cell-penetrating TAT sequence was tethered to the peptides with the amino acids, RKKRRQRRR-(6-aminohexanoic acid).
Animal Models
In vitro studies
Freshly isolated myocytes from 8-week-old male C57BL mice were used for all fluorescent studies. 21, 22 Animals were anesthetized with intraperitoneal injection of pentobarbitone sodium (240 mg/kg) before excision of the heart, as approved by the animal ethics committee of 
In vivo studies
Adult Fischer rats weighing %250 g were used for all in vivo infarct size and contractility studies. Animals were anesthetized with 50 mg/kg of sodium pentobarbital, as approved by The UCLA Chancellor's Office of Animal Research Oversight in accord with the USPHS Policy and the Guide for the Care and Use of Laboratory Animals. A total number of 46 rats were used.
Ischemia-Reperfusion
In vitro
Intact ventricular myocytes were exposed to 40 lmol/L of H 2 O 2 for 5 minutes, followed by 10 U/mL of catalase (CAT) to degrade the H 2 O 2 , to mimic the effect of a transient OS in vivo associated with I/R injury, as previously described. 10 
Ex vivo studies
Hearts excised from guinea pigs were perfused retrogradely by a Langendorff apparatus. Hearts were exposed to 30 minutes of coronary perfusion with calcium-containing Krebs-Henseleit buffer solution at 7 mL/min, followed by 30 minutes of no-flow ischemia and, finally, 30 minutes of reperfusion. AID-TAT peptide or AID(S)-TAT peptide (1 or 10 lmol/L) was administered immediately upon reperfusion.
In vivo studies
MI was induced under aseptic conditions in Fischer rats with ligation of the coronary artery for 30 minutes using methods adapted from previous studies. 23, 24 Three minutes after reperfusion, AID-TAT peptide or AID(S)-TAT peptide, or saline, was injected into the chamber of the left ventricle (LV) such that the final circulating concentration of the peptide in the blood of the rat was 1 or 10 lmol/L, the chest was closed, and the rats were allowed to recover for up to 12 weeks. 
Measurement of Intracellular Calcium
Measurement of Superoxide
Superoxide generation was assessed in myocytes using fluorescent DHE (5 lmol/L, 515 to 560-nm excitation filter, 590-nm long-pass emission) at 37°C, as previously described. 10 
Measurement of Mitochondrial Flavoprotein Oxidation
Flavoprotein autofluorescence was used to measure flavoprotein oxidation in myocytes at 37°C based on previously described methods (excitation 480 nmol/L, emission 535 nm). 25 Fluorescent images were taken at 1-minute intervals with 1.5 seconds of exposure on a Hamamatsu Orca ER digital camera (Hamamatsu Photonics, K.K.) attached to an inverted Nikon TE2000-U microscope (Nikon Corporation). MetaMorph 6.3 (Molecular Devices) was used to quantify the signal by manually tracing myocytes. An equivalent region not containing cells was used as background and was subtracted. Fluorescent values recorded over 5 minutes before and 7 minutes after addition of drugs were averaged and alterations in fluorescent ratios reported as percentage increase from the basal average. FCCP (10 lmol/L) was added at the end of each experiment to achieve a maximum fluorescence value indicative of maximum flavoprotein oxidation.
Measurement of Mitochondrial NADH
Autofluorescence of NADH was monitored in myocytes at 37°C, as previously described (excitation 365 nmol/L, emission 460/535 nm). 12 Fluorescence at 365-nm exciation and 460/535-nm emission were measured at 1-minute intervals with 1.5 seconds of exposure on a Hamamatsu Orca ER digital camera (Hamamatsu Photonics, K.K.) attached to an inverted Nikon TE2000-U microscope (Nikon Corporation). Ratiometric 460/535-nm signal of individual myocytes were quantified using MetaMorph 6.3 (Molecular Devices) to measure signal intensity of manually traced myocytes. An equivalent region not containing cells was used as background and was subtracted. Fluorescent ratios recorded over 3 minutes before and 7 minutes after treatments were averaged and alterations in fluorescent ratio were reported as percentage increase from the baseline average. To confirm that the NADH signal was indicative of mitochondrial NADH production, 4 mM of sodium cyanide was added at the end of each experiment to deplete mitochondria of NADH after collapse of Ψ m .
Creatine Kinase and Lactate Dehydrogenase Assays
Creatine kinase (CK) and lactate dehydrogenase (LDH) levels were determined from perfusate from ex vivo hearts before and after ischemia, as previously described. 4 CK activity was determined using a Randox CK N-acetyl-L-cysteine-activated diagnostic kit (Randox Laboratories Ltd., Crumlin, UK). 
Measurement of Infarct Size
Following ex vivo or in vivo I/R protocols, hearts were stained with 0.1% nitroblue tetrazolium dye to assess infarct size. Area of damage was quantitated using ImageJ software (National Institutes of Health, Bethesda, MD) and reported as percentage (%) of LV area.
Glutathione Assay
Reduced glutathione/oxidized glutathione (GSH/GSSG) ratio was determined in ischemia-reperfused hearts based on previously described methods. 4, 26 Tissue homogenates were centrifuged at 80009g for 10 minutes at 4°C, and GSH/ GSSG ratio was measured from the supernatant. Fluorescence was detected using a spectrophotometer (PowerWave XS; BioTek) at 412 nm.
Contractility Studies
Ex vivo LV pressure (LVP) was assessed in guinea pig hearts exposed to I/R by inserting a fluid-filled latex balloon connected to a pressure transducer into the left ventricular chamber. LVP measurements were recorded using a PowerLab data acquisition system and LabChart7 (ADInstruments, Bella Vista, NSW, Australia). The balloon was inflated to an end-diastolic pressure of 10 mm Hg, and the volume was maintained throughout the experiment. Coronary perfusion was maintained at 7 mL/min. LV developed pressure was calculated as follows: max pressure (mm Hg)-min pressure (mm Hg).
In vivo
Ventricular function was assessed at 12 weeks post-MI (end of study) by catheterization of the LV with a 2.0-Fr catheter (Millar Instruments, Houston, TX), as previously described. 23 Rats were anesthetized with isoflurane, intubated, the chest opened, and the Millar catheter inserted directly into the LV through a 20-Ga angiocatheter. After stabilization, LVPs, contractility, and relaxation (AEdP/dT) data were acquired and analyzed with HEM V4.2 software (Notocord Systems, Croissy sur Seine, France). All hemodynamic data were recorded continuously for at least 30 minutes to ensure physiological levels of pressures and heart rates. For the peptide control study without an infarct, a femoral artery was also catheterized for pressure recording and peptide infusion. At the end of the functional evaluation, the rat was euthanized with an overdose of anesthetic, the hearts removed, weighed, and stained for infarct size.
Statistical Analysis
Results are reported as meanAESEM. Statistical comparisons of responses between unpaired data were made using the Student's t-test or between groups of cells using 1-way ANOVA and Tukey's post-hoc test. Where sample sizes were small and did not fit a Gaussian distribution, we used the nonparametric Kruskal-Wallis test, followed by Dunn's multiple comparison test to identify the significant data (GraphPad Prism version 3.02; GraphPad Software, Inc., La Jolla, CA).
Results
AID-TAT Peptide Decreases I/R Injury in Hearts Ex Vivo
We examined the effect of a single application of 1 lmol/L of AID-TAT peptide injected into the coronaries through the aorta within 5 minutes after commencement of reperfusion in hearts exposed to 30 minutes of no-flow ischemia on a Langendorff apparatus. In hearts exposed to active peptide, infarct size was significantly decreased, compared to hearts exposed to 1 lmol/L of scrambled peptide (AID(S)-TAT) ( Figure 1A and 1B). Release of CK ( Figure 1C ) and LDH ( Figure 1D ) was significantly less in hearts exposed to active peptide. However, the ratio of GSH/GSSG was not altered after administration of 1 lmol/L of AID-TAT. When the concentration of the active peptide was increased to 10 lmol/L, GSH increased, suggesting an attenuation of OS ( Figure 1E) . 
AID-TAT Peptide Improves Developed Pressure in Hearts Ex Vivo
We examined the effect of AID-TAT peptide on contractility ex vivo in hearts exposed to ischemia then reperfusion. In hearts exposed to scrambled peptide, developed pressure decreased during reperfusion and did not improve during the 30 minutes after ischemia (Figure 2A and 2B) . Application of 1 lmol/L of AID-TAT had no effect on postischemia recovery; however, 10 lmol/L of AID-TAT significantly improved developed pressure 20 to 30 minutes after ischemia ( Figure 2D and 2E). Application of 10 lmol/L of AID-TAT peptide did not alter developed pressure over 60 minutes in the absence of I/R ( Figure 2E) . 
Effect of AID-TAT Peptide on Calcium Influx In Vitro
Because AID-TAT peptide slows the inactivation rate of I Ca-L current, 19, 20 Figure 3A and 3B). Application of 1 lmol/L of AID-TAT peptide had no effect on the increase in Fura-2 signal induced by 40 lmol/L of H 2 O 2. However, the addition of 10 lmol/L of AID-TAT peptide attenuated the increase in Fura-2 signal induced by H 2 O 2 by %75% ( Figure 3C and 3D) . Application of AID-TAT peptide did not alter basal Fura-2 signal, indicating that the peptide did not prevent calcium influx through the alpha subunit of the channel ( Figure 3D , inset right). These data suggest that 10 lmol/L, but not 1 lmol/L, of AID-TAT peptide can alter I Ca-L -activated calcium influx in myocytes.
Effect of AID-TAT Peptide on Cellular Superoxide In Vitro
We have shown previously that 5 minutes of exposure of myocytes to H 2 O 2 results in a significant further increase in superoxide assessed as changes in dihydroethidium (DHE) fluorescence in guinea pig ventricular myocytes. 10, 30 The further increase in superoxide occurred as a result of increased calcium uptake into mitochondria, increased reduction of NAD + , and increased electron flow into mitochondrial complex II. 30 We assessed the effect of AID-TAT peptide on DHE fluorescence in ventricular myocytes from C57BL mice. Application of 40 lmol/L of H 2 O 2 resulted in 70.3AE25.1% further increase in DHE signal that was completely attenuated with nisoldipine ( Figure 4A and 4B) . Application of the superoxide scavenger, N-tert-butyl-a-phenyl-nitrone (PBN), completely abolished DHE signal, confirming specificity of the indicator for superoxide ( Figure 4B , inset right). Application of 1 lmol/L of AID-TAT peptide had no effect on the H 2 O 2 -induced increase in DHE signal, but 10 lmol/L of AID-TAT peptide significantly attenuated the increase in DHE signal ( Figure 4C and 4D) . AID-TAT peptide had no effect on the DHE signal in the absence of H 2 O 2 , indicating that basal production of superoxide was unaffected by the peptide ( Figure 4D , inset right).
Effect of AID-TAT Peptide on Reduction of NAD + to NADH In Vitro
We assessed changes in mitochondrial NADH as autofluorescence in myocytes. Consistent with previous results, 19 addition of H 2 O 2 significantly increased NADH signal that could be attenuated with nisoldipine ( Figure 5A and 5B).
Collapse of the signal with addition of NaCN indicated that the signal was mitochondrial in origin. Application of 1 and 10 lmol/L of AID-TAT peptide attenuated the increase in NADH associated with application of H 2 O 2 ( Figure 5C and 5D). This suggested that AID-TAT peptide was altering NADH as a result of effects on MMP or oxygen consumption.
Effect of AID-TAT Peptide on Ψ m and Flavoprotein Oxidation In Vitro
We assessed effects of the peptide on Ψ m assessed as changes in JC-1 fluorescence. Consistent with previous work, 10 (Figure 7E) . 19 This is a measure of oxygen consumption, suggesting that the peptide can decrease metabolic activity in myocytes.
AID-TAT Peptide Decreases Infarct Size and Supports Contractility In Vivo
Rats underwent coronary artery ligation, and within 5 minutes after commencement of reperfusion, 1 or 10 lmol/L of AID-TAT peptide or AID(S)-TAT peptide was injected into the LV.
The chest was closed, and rats were allowed to recover for up to 12 weeks. In a group of rats, saline was injected instead of peptide ("saline"), and in another group of rats, the chest was opened and closed without undergoing cardiac surgery and rats were allowed to recover ("sham"). Before sacrifice, ventricular function (LVPs and AEdP/dT) was assessed after catheterization of the LV. At the time of sacrifice, hearts were excised and weighed and infarct size was assessed. Consistent with our ex vivo data, rats treated with 1 or 10 lmol/L of AID-TAT peptide had significantly smaller infarcts than rats treated with AID(S)-TAT peptide ( Figure 8A and 8B). This was evident at 6 and 12 weeks after CAL ( Figure 8B ). At 12 weeks, heart/body weight ratios were larger in rats treated with AID(S)-TAT, compared to rats treated with AID-TAT peptide ( Figure 8C ). More important, left ventricle systolic pressure LVSP ( Figure 8D ) and max dP/dT (Figure 8E) were significantly improved at 12 weeks post-CAL in rats treated with 10 lmol/L of AID-TAT peptide. Because the AID-TAT peptide also binds the smooth muscle isoform of I Ca-L , we tested whether the peptide acutely altered arterial blood pressure in rats. After dual catheterization of the femoral artery and LV, rats were injected intravenously with 1 lmol/L 
Discussion
In the heart, L-type calcium channels are composed of the ionconducting and pore-forming Ca v 1. auxiliary subunit is an effective modulator of channel inactivation and open probability. [31] [32] [33] The discovery of a sequence motif in the I-II loop of the Ca v 1.2 alpha-interacting domain revealed the contact point for the auxiliary b 2 subunit. 34 The motif is highly conserved in all a 1 subunits. Therefore, a peptide was synthesized that interferes with the binding of the b subunit to the I-II linker of the a 1C subunit with the purpose of studying the biophysical modulation of the currents through the a subunit by the b subunit. 20 We and others have demonstrated that application of the AID peptide slows the inactivation rate of the L-type calcium current and decreases open probability of single-channel currents. 19, 20, 22 In addition, the b subunits of voltage-dependent calcium channels are members of the membrane-associated guanylate kinase family of proteins that are known scaffolding proteins with a type-3 Sarc homology domain and a guanylate kinase domain. 35, 36 It is currently recognized that a number of structural proteins directly interact with the b subunit, including members of the Gem/Kir family and the large subsarcolemmal structural protein, AHNAK. 37 Therefore, it is reasonable to argue that the b subunit of the channel can modulate calcium-current activation and inactivation kinetics, in addition to influencing structural proteins that it associates with. We have found that activation of I Ca-L can modulate mitochondrial function. This occurs as a result of increased calcium influx and influences NADH production, superoxide production, and metabolic activity. 19 We also found that activation of the channel caused an increase in MMP. This was mediated through the movement of cytoskeletal proteins because depolymerization of F-actin filaments or application of AID-TAT peptide (that immobilises the b subunit and induces functional uncoupling from F-actin) attenuated the response. 19 Because I/R injury is associated with an increase in metabolic activity and OS, we hypothesized, in this study, that application of AID-TAT peptide can alter I/R injury by an effect on mitochondrial function. We demonstrate that application of 1 lmol/L of AID-TAT can decrease infarct size in guinea pig hearts exposed to I/R ex vivo and in rats that had undergone CAL in vivo (Figures 1 and 8) . Application of AID-TAT peptide decreased mitochondrial NADH production ( Upon binding of the peptide, the b-AID complex dissociates from the a subunit, resulting in rapid removal. 20 Because the turnover rate of the channel complex in vivo is %96 hours, 38 we can presume that the duration of the loss of b subunits after a single injection of the peptide will be %3 to 4 days after infarction.
We demonstrate that heart/body weight ratio does not increase and contractility is supported for up to 12 weeks in rats injected with 10 lmol/L of AID-TAT that had undergone CAL in vivo. Contractility appears to normalize early after administration of the peptide, as evidenced by an improvement in developed pressure within 30 minutes after ischemia in hearts that had undergone I/R injury ex vivo (Figure 2) . We propose that the improvement in contractile function occurs as a result of a decrease in OS and metabolic activity in the hearts. Alterations in [Ca 2+ ] i after application of AID-TAT were not deleterious because intravenous injection of the peptide did not alter arterial pressure during continuous recordings in rats in vivo ( Figure 8F ) or in hearts perfused with the peptide ex vivo in the absence of I/R ( Figure 2E ). The sequence motif in the I-II loop of the Ca v 1.2 is highly conserved across species. In this study, we have demonstrated a beneficial effect of the peptide in guinea pig heart, mouse myocytes, and rats. The reduction in infarct size and improvement in contractility after administration of the peptide could provide significant benefits post-MI in the human heart.
